Povidone-Iodine Versus Chlorhexidine in Surgical Wound Care

Last updated: April 21, 2025
Sponsor: University of Jaén
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Chlorhexidine

Povidone-Iodine

Povidone-Iodine and Chlorhexidine Antiseptic Treatment for Surgical Wound Management

Clinical Study ID

NCT06667089
University of Jaén¨
  • Ages 18-45
  • All Genders

Study Summary

This comparison examines the effectiveness of povidone-iodine and chlorhexidine in managing iatrogenic wounds in surgical patients. Both antiseptics are commonly used to prevent postoperative infections, but they differ in mechanism, efficacy, and safety profiles. Povidone-iodine releases iodine, which acts broadly against bacteria, viruses, and fungi, while chlorhexidine disrupts cell membranes, providing rapid bactericidal action. Studies suggest that chlorhexidine may offer longer-lasting antibacterial effects, but povidone-iodine has a wider antimicrobial range. Optimal choice depends on patient needs, wound type, and potential for adverse reactions, emphasizing the need for tailored antiseptic strategies in wound care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Elderly patients undergoing surgical procedures resulting in iatrogenic wounds (surgical wounds of various specialties, such as abdominal, orthopedic,cardiovascular, etc.).

  • Availability for follow-up during the postoperative period, ensuring attendance atmedical check-ups for the evaluation of healing and prevention of infections.

  • Ability to provide informed consent, understanding the objectives, risks andbenefits of the study.

  • Absence of previous infections at the surgical site, ensuring that the wounds arerecent and derived from the current surgical procedure.

Exclusion

Exclusion Criteria:

  • Known allergies or hypersensitivity to povidone iodine or chlorhexidine, to avoidrisks of serious adverse reactions.

  • Immunocompromised patients, such as those with advanced HIV, on immunosuppressanttreatment, or with decompensated chronic diseases (poorly controlled diabetes,kidney failure, etc.), due to increased susceptibility to infections and alteredhealing.

  • Patients with active infections or infected wounds prior to surgery, to avoidbiasing the results by pre-existing infections.

  • Pregnancy or breastfeeding, due to safety considerations and the possible alterationof healing and immunity processes during these stages.

  • Use of other antiseptics or topical treatments at the wound site that may interferewith the efficacy of povidone iodine or chlorhexidine.

  • Patients with known wound healing disorders (such as autoimmune diseases orhematological disorders), which may affect the results in terms of healing time andquality.

Study Design

Total Participants: 107
Treatment Group(s): 3
Primary Treatment: Chlorhexidine
Phase:
Study Start date:
January 07, 2025
Estimated Completion Date:
April 04, 2025

Connect with a study center

  • María Juana Millán Reyes

    Jaén, 23007
    Spain

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.